William Gooding
机构: UPMC Hillman Cancer Center
每年引用次数
引用次数
引用: 29,450
H-指数: 92
I10-指数 : 242
出版物: 398
p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma
A. V. Safatle-Ribeiro , M. C. Posner , W. E. Gooding , U. Ribeiro
Annual Cancer Symposium of the Society of Surgical Oncology 83 ( 1) 7 -18
1998
Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial
G. S. Chatta , T. M. Feinstein , L. J. Appleman , D. M. Friedland
Journal of Clinical Oncology 26 ( 15_suppl) 5148 -5148
5
2008
Analysis of Changes in Eating Behavior and Weight Loss in Type II Diabetic Patients: Which Behaviors to Change
J. C. Guare , R. R. Wing , M. D. Marcus , L. H. Epstein
Diabetes Care 12 ( 7) 500 -503
48
1989
Plasminogen Activator and Its Inhibitor in Cancer Patients Treated With Tumor Necrosis Factor
T. F. Logan , M. A. Virji , W. E. Gooding , F. A. Bontempo
Journal of the National Cancer Institute 84 ( 23) 1802 -1810
4
1992
Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial
T. L. Gillison , L. J. Appleman , D. M. Friedland , T. L. Evans
Journal of Clinical Oncology 27 ( 15_suppl) e16086 -e16086
1
2009
Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.
M. Korytkowski , A. Thomas , L. Reid , M. B. Tedesco
Diabetes Care 25 ( 9) 1607 -1611
55
2002
Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC)
M. K. Mohamed , S. Ramalingam , Y. Lin , W. E. Gooding
Journal of Clinical Oncology 22 7097 -7097
10
2004
Statistical evaluation of a molecular classification tool for discriminating cancer recurrence versus new primary cancer formation.
E. M. Ellsworth , W. E. Gooding , D. M. Smith , W. Spence
Journal of Clinical Oncology 28 ( 15_suppl) e21059 -e21059
2010
Phase II trial of doxorubicin (D) and bortezomib (B) in patients with incurable adenoid cystic carcinoma of the head and neck.
A. P. Kotsakis , W. E. Gooding , A. Argiris
Journal of Clinical Oncology 28
2
2010
Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter phase II study.
A. Pennathur , R. I. Whyte , A. Zajac , D. G. Brachman
Journal of Clinical Oncology 28
2010
A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa).
A. K. Patel , L. J. Appleman , W. E. Gooding , D. Friedland
Journal of Clinical Oncology 29 2564 -2564
2011
Phase II study of irinotecan and paclitaxel for patients with recurrent small cell lung cancer (SCLC)
T. K. Owonikoko , S. Ramalingam , J. Forster , Y. Shuai
Journal of Clinical Oncology 25 18011 -18011
2007
A phase II study of arsenic trioxide (ATO) in patients with metastatic melanoma
A. A. Tarhini , J. M. Kirkwood , W. E. Gooding , J. J. Stuckert
Journal of Clinical Oncology 25 8569 -8569
1
2007
Molecular detection of occult nodal metastases in esophageal adenocarcinoma
I. Altomare , A. Pennathur , L. Xi , W. E. Gooding
Journal of Clinical Oncology 25 ( 18_suppl) 4540 -4540
2007
Intratumoral epidermal growth factor receptor (EGFR) antisense (AS) DNA in recurrent squamous cell carcinoma of the head and neck (SCCHN): A phase I trial
S. Y. Lai , V. W. Lui , P. J. Koppikar , S. M. Thomas
Journal of Clinical Oncology 25 6009 -6009
3
2007
Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis.
R. L. Ferris , D. E. Heron , S. Kim , M. K. Gibson
Journal of Clinical Oncology 28 5515 -5515
7
2010
Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results and correlation with TS, MTHFR, and VEGF gene polymorphisms.
A. Argiris , M. Karamouzis , W. E. Gooding , B. Branstetter
Journal of Clinical Oncology 28 5533 -5533
3
2010
Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter study.
A. Pennathur , R. I. Whyte , A. Zajac , D. G. Brachman
Journal of Clinical Oncology 28 7080 -7080
2010
Phase II evaluation of tremelimumab (Treme) combined with high-dose interferon alpha-2b (HDI) for metastatic melanoma.
A. A. Tarhini , S. J. Moschos , H. Tawbi , Y. Shuai
Journal of Clinical Oncology 28 8524 -8524
15
2010
Constitutive Activation of Stat5b Contributes to Carcinogenesis in Vivo
Thomas E. Smithgall , Jennifer Rubin Grandis , Sichuan Xi , William E. Gooding
Cancer Research 63 ( 20) 6763 -6771
154
2003